Thursday, 19 April 2018 - 10:29
  • it
  • de
  • en
  • fr

Takeda

Novo Nordisk offers €2.6bn for Belgium-based Ablynx

The Belgian biotech sector appears to be fairly attractive to the big pharma. After last Friday’s announcement that Takeda had acquired Belgium-based Tigenix for €520m, Denmark-based Novo Nordisk has announced today it has offered €2.6bn for Belgian biotech company Ablynx….

First large acquisition of the year: Takeda acquires Tigenix for €520m

Belgian-Spanish biotech company TiGenix NV and Takeda Pharmaceutical have jointly announced today, before trading opened, that Takeda is planning to purchase all TiGenix shares at €1.79 per share, which means setting TiGenix’s value at approximately €520m. TiGenix’s key asset is…

Takeda announces clinical trial for anti-Zika vaccine

Japan-based Takeda has announced a Phase I clinical trial for its anti-Zika (TAK-426) vaccine. The trial will have a minimum duration of 15 months and will be partly funded by the US Department of Health and Human Services, the Office…

NASH: Takeda signs agreement with HemoShear

Takeda Pharmaceutical and HemoShear Therapeutics, a private biotech company, have signed a collaboration agreement aimed at discovering and developing new therapies for liver diseases, including NASH. HemoShear’s REVEAL-Tx platform applies principles of physiological blood flow to tissue from patients. This…

Samsung Bioepis announces important agreement with Takeda

Samsung Bioepis, part of South-Corea-based Samsung, today issued an important press release to announce it signed an agreement with Japan-based Takeda Pharmaceuticals to develop new drugs. Bioepis, founded in 2012, only focused on developing biosimilars up to now, and the…

Takeda to dismiss 480 sales managers and representatives in US

The US unit of Takeda Pharmaceuticals is completing a restructuring plan leading to dismiss 480 sales managers and representatives. The plan reflects the new policy pursued by Takeda CEO Cristopher Weber, who intends to focus more on cancer treatment. (Source:…

Takeda doesn’t stop and seeks new acquisitions

Christophe Weber, CEO of Japan-based drugmaker Takeda, said in an interview to German daily Frankfurter Allgemeine Zeitung that his group is seeking to perform new acquisitions shortly, in order to ensure growth in the US, Europe and Japan. Weber added…

Takeda targets Tigenix

Belgium-based Tigenix reportedly attracted interest from Japan-based group Takeda, Tigenix CEO Eduardo Bravo reported to Belgian daily De Tijd, adding that talks started as early as last year, when Takeda invested €25m in Tigenix. Tigenix focuses on developing anti-inflammatory therapies…

Takeda concludes original agreement to outsource drug development

Japan-based Takeda announced on an interesting press release it will outsource the development of drugs targeting pediatric epilepsy to US-based Ovid Therapeutics. The agreement mainly provides for the development of TAK-935, an investigational drug inhibiting the enzyme cholesterol 24-hydroxylase (CH24H),…

Valeant-Takeda’s $10bn deal to sell Salix fails

Valeant renounced to sell its gastrointestinal business unit Salix to Takeda for $10bn. Indeed, talks between the groups reportedly failed, since Valeant is reluctant to provide financial details about Salix. Shares in Valeant instantly lost nearly 9%, which proves that…

Takeda ready to acquire Valeant’s Salix for $10bn

Japan-based Takeda is reported to be in advanced talks with Valeant to acquire Salix Pharmaceuticals. The rumors started circulating yesterday night, when Valeant’s management confirmed ongoing talks about Salix. Valeant’s shares soon rose by almost 30%, even though selling Salix…

Takeda, Affilogic partner to develop therapies for neurological diseases

Takeda Pharmaceutical Company and Affilogic have entered into a research collaboration to develop therapies targeting the central nervous system. Affilogic is a private company specialized into the research and development of a novel class of proteins named Nanofitins – potent…

Takeda ready to spend $15-20bn for a takeover in the US

Japan-based Takeda is reported to be sounding out the US market in search for a takeover target for which it would be ready to spend up to $15-20bn (the group has a $7bn debt), in order to become more influent…

iBData, Takeda’s new program to manage IBD

Takeda has stated that it is partnering with Vanderbilt University and Texas Digestive Disease Consultants (TDDC) in order to develop a digital program to help patients and physicians manage IBD (inflammatory bowel disease). The pilot program, iBData, which will initially…

Takeda begins extensive trial for new vaccine against Dengue

Takeda, the major Japanese pharma group, has started an important three-year clinical trial for the vaccine against dengue, including vaccination of 20,000 children in Asia and Latin America. The new vaccine TAK-003, developed by Takeda, will provide an alternative to…